256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699)

• Hong Zhang,
• Robert Wesolowski,
• Cesar Perez,
• Breelyn Wilky,
• Waldo Ortuzar Feliu,
• Remigiusz Kaleta,
• Jonathan Trent

Affiliations

Hong Zhang

5 Translational Tissue Engineering Center, Wilmer Eye Institute and the Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA

Robert Wesolowski

Aff1 Division of Medical Oncology B401 Starling Loving Hall, W10th Avenue 43210 Columbus OH USA

Cesar Perez

1University of Miami Miller School of Med, Miami, FL, USA

Breelyn Wilky

3University of Colorado Anschutz Medical, Aurora, CO, USA

Waldo Ortuzar Feliu

4Agenus inc, Lexington, Massachusetts, USA

Remigiusz Kaleta

4Agenus inc, Lexington, Massachusetts, USA

Jonathan Trent

1University of Miami Miller School of Med, Miami, FL, USA